A previously healthy girl aged 15 years presented with a 3-month history of low back pain, lethargy, morning stiffness and nocturnal back discomfort. She had no significant history of weight loss, infective symptoms or neurological symptoms, including bladder or bowel incontinence. There was no recent travel history.
DESCRIPTION
A previously healthy girl aged 15 years presented with a 3-month history of low back pain, lethargy, morning stiffness and nocturnal back discomfort. She had no significant history of weight loss, infective symptoms or neurological symptoms, including bladder or bowel incontinence. There was no recent travel history.
Examination revealed normal temperature and mild focal tenderness over the midline lumbar spine, with normal range of motion. There was isolated weakness in left hip flexion, and no other neurological findings. Blood tests showed a normal white cell count (6.6×10 9 /L), elevated erythrocyte sedimentation rate (38 mm/hour) and slightly elevated C reactive protein (11 mg/L, normal<10 mg/ L). X-rays were unremarkable. A limited CT of L3 showed diffuse sclerosis of its spinous process with areas of lytic destruction and mild effacement of the paravertebral fat pads (figure 1). Serial blood cultures were negative for microorganisms. Subsequent empirical antibiotics with intravenous flucloxacillin were initiated for presumed infective osteomyelitis.
Further assessment with MRI lumbar spine showed an abnormality at the L3 level, with expansion of the L3 lamina and spinous process, and an area of low T1 signal with corresponding high T2 signal within (figure 2). There was enhancement of this area postcontrast imaging, and adjacent paraspinal oedema without features of malignancy. Whole-body bone scan demonstrated focal abnormal uptake in the L3 spinous process, left sacral ala, left ilium and right proximal tibia ( figure 3 ). Given the multifocality of the metabolically active bone lesions, combined with the relatively benign history and normal biochemistry, the diagnosis of chronic recurrent multifocal osteomyelitis (CRMO) was made. Antibiotics were ceased after 3 days and the patient underwent treatment with non-steroidal anti-inflammatory drugs (NSAIDs), followed by a tapering regimen of prednisolone 10 mg and physical therapy. At 6 months follow-up, she experienced a significant reduction in symptoms and improved quality of life. CRMO is a rare auto-inflammatory disorder which typically affects children (median age 10 years old). CRMO is characterised by non-bacterial multifocal osseous lesions which may mimic chronic osteomyelitis. It is often seen in the metaphysis of long bones, clavicles, vertebral bodies and pelvis. 1 There may be an association with several autoimmune diseases such as psoarisis, inflammatory bowel disease and granulomatosis.
A combination of imaging techniques such as plain radiographs, MRI and bone scintigraphy are useful in the diagnosis of CRMO. As CRMO is a diagnosis of exclusion, it may be difficult to exclude diagnoses such as infective osteomyelitis and neoplasms on imaging alone, and biopsies can be considered for confirmation. MRI is useful in CRMO monitoring highlighting the extent of disease as it is highly sensitive and specific for inflammatory abnormalities. Other advantages include no ionising radiation and better characterisation of bone marrow lesions. 2 NSAIDs are considered the most suitable treatment of CRMO, and in 80% of patients have been shown to relieve symptoms. 3 In cases of relapse and recurrent symptoms in patients with NSAID treatment, other pharmaceutical interventions such as bisphosphonates, corticosteroids, methotrexate, interferon and TNF-α inhibitors have shown some efficacy. 1 
Learning points
▸ Chronic back pain in children should be investigated promptly and include a careful and thorough clinical assessment for paediatric red flags. ▸ Initial imaging with an X-ray should be performed. MRI and bone scintigraphy are useful adjuncts to aid in the early diagnosis of chronic recurrent multifocal osteomyelitis (CRMO) to avoid unnecessary invasive diagnostic tests or aggressive therapy. ▸ CRMO is a rare non-bacterial disease with multifocal lesions.
It is identified in long tubular bones, clavicle and pelvis and most commonly in long bone metaphyseal lesions.
Importantly, infection and malignancy should be excluded. ▸ Combination treatment may be required in treating CMRO.
First-line therapy with non-steroidal anti-inflammatory drugs should be considered, and if relapse occurs, disease-modifying agents such as methotrexate, bisphosphonates and corticosteroids may be used. 
